文献速递治疗药物监测与药物基因组学特殊人群用药

基于生理药代动力学模型预测达托霉素在皮肤与骨组织中的暴露及药效

Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues.
PubMed 文献 · Clin Pharmacokinet · 2022-08-16

本研究利用PK-Sim®构建达托霉素生理药代动力学模型,整合既往研究中的血浆与骨组织浓度数据进行验证,并模拟6、8、10、12 mg/kg/24 h剂量在血液、皮肤和骨组织的药代动力学及靶值 attainment 概率。结果显示高剂量(≥10或≥12 mg/kg)对特定病原及感染部位更可能达标,但需关注安全性并借助治疗药物监测优化个体暴露。

要点

  • 达托霉素在骨与关节感染中需更高剂量以优化骨组织暴露。
  • 对于金黄色葡萄球菌MIC>0.5 mg/L菌血症,建议剂量≥10 mg/kg。
  • 骨与关节感染或复杂性皮肤感染建议剂量≥12 mg/kg。

核心结论

  • 首次建立达托霉素骨与关节感染的PBPK/药效模型,证实优化骨组织暴露需要更高剂量。
  • 高剂量可能带来安全性问题,治疗药物监测和模型引导精准给药对确保个体化适宜暴露是必要的。

研究设计与样本

  • 基于PK-Sim®构建达托霉素PBPK模型,使用既往三项已发表研究的血浆和骨浓度数据进行构建与 refine。
  • 利用常规诊断图进行内部验证,最终模型模拟6、8、10、12 mg/kg/24 h剂量在1000名受试者中的药代动力学。

主要发现

  • 最终模型对血液、皮肤和骨组织所有药代动力学参数的绝对平均折叠误差均在0.5至2之间,拟合良好。
  • 剂量模拟显示,对于MIC>0.5 mg/L的金黄色葡萄球菌或MIC>1 mg/L的粪肠球菌所致菌血症,应使用≥10 mg/kg剂量。
  • 骨与关节感染或复杂性皮肤感染应使用≥12 mg/kg剂量。
  • 当考虑较低MIC时,6-8 mg/kg剂量可能达到足够成功率。
  • 对于MIC>2 mg/L的粪肠球菌感染,需更高剂量和联合治疗以最大化疗效。

关键数值与推荐

  • 金黄色葡萄球菌菌血症且MIC>0.5 mg/L时,推荐达托霉素剂量≥10 mg/kg。
  • 粪肠球菌菌血症且MIC>1 mg/L时,推荐达托霉素剂量≥10 mg/kg。
  • 骨与关节感染或复杂性皮肤感染时,推荐达托霉素剂量≥12 mg/kg。
  • 较低MIC时,6-8 mg/kg剂量可能达到足够成功概率。
  • 粪肠球菌感染且MIC>2 mg/L时,需更高剂量联合治疗。

临床怎么用

  • 临床可根据感染部位和病原MIC参考模拟结果选择达托霉素剂量(如菌血症≥10 mg/kg,骨与关节感染≥12 mg/kg)。
  • 使用高剂量达托霉素时应关注安全性,并考虑开展治疗药物监测和模型引导精准给药以确保个体暴露适宜。

局限性

  • 模型构建依赖于既往已发表研究的数据,可能受数据来源限制。
  • 高剂量方案的安全性顾虑尚未在模拟中充分评估,需临床监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Daptomycin has been recommended in the treatment of bone and joint infection. Previous work showed that the approved dosage of daptomycin may be insufficient to achieve optimal exposure in patients with bone and joint infection. However, those studies assumed that bone exposure was similar to steady-state daptomycin-free plasma concentrations. We sought to establish a physiologically based pharmacokinetic (PBPK) model of daptomycin to describe the dynamics of daptomycin disposition in bone and skin tissue. METHODS: A PBPK model of daptomycin was built using PK-Sim®. Daptomycin concentrations in plasma and bone were obtained from three previously published studies. Physicochemical drug characteristics, mass balance, anthropometrics, and experimental data were used to build and refine the PBPK model. Internal validation of the PBPK model was performed using the usual diagnostic plots. The final PBPK model was then used to run simulations with doses of 6, 8, 10, and 12 mg/kg/24 h. Pharmacokinetic profiles were simulated in 1000 subjects and the probabilities of target attainment for the area under the concentration-time curve over the bacterial minimum inhibitory concentration were computed in blood, skin, and bone compartments. RESULTS: The final model showed a good fit of all datasets with an absolute average fold error between 0.5 and 2 for all pharmacokinetic quantities in blood, skin and bone tissues. Results of dosing simulations showed that doses ≥10 mg/kg should be used in the case of bacteremia caused by Staphylococcus aureus with a minimum inhibitory concentration >0.5 mg/L or Enterococcus faecalis with a minimum inhibitory concentration >1 mg/L, while doses ≥12 mg/kg should be used in the case of bone and joint infection or complicated skin infection. When considering a lower minimum inhibitory concentration, doses of 6-8 mg/kg would likely achieve a sufficient success rate. However, in the case of infections caused by E. faecalis with a minimum inhibitory concentration >2 mg/L, a higher dosage and combination therapy would be necessary to maximize efficacy. CONCLUSIONS: We developed the first daptomycin PBPK/pharmacodynamic model for bone and joint infection, which confirmed that a higher daptomycin dosage is needed to optimize exposure in bone tissue. However, such higher dosages raise safety concerns. In this setting, therapeutic drug monitoring and model-informed precision dosing appear necessary to ensure the right exposure on an individual basis.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Garreau R, Montange D, Grillon A, et al. Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues. Clin Pharmacokinet. 2022. PMID: 35972685. doi:10.1007/s40262-022-01168-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。